Brief: Compass Pathways Announces Completion Of Recruitment For The Phase 3 COMP005 Trial Of COMP360 Psilocybin For Treatment-Resistant Depression
26/03/2025 11:54
March 26 (Reuters) - Compass Pathways PLC CMPS.O: COMPASS PATHWAYS ANNOUNCES COMPLETION OF RECRUITMENT FOR THE PHASE 3 COMP005 TRIAL OF COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION COMPASS PATHWAYS PLC: ON TRACK FOR TOP-LINE 6-WEEK PRIMARY ENDPOINT RESULTS IN LATE Q2 COMPASS PATHWAYS PLC - COMP006 26-WEEK DATA EXPECTED IN SECOND HALF OF 2026 Source text: ID:nBwcfJCBTa Further company coverage: CMPS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on COMPASS Pathways
See all newsCompass Pathways PLC reports results for the quarter ended September 30 - Earnings Summary
Corrected: Compass Pathways Q3 net loss narrows on lower R&D charges
Corrected: BRIEF-COMPASS Pathways Q3 EPS USD -0.31
Psychedelic drug developers fall after Usona submits depressive drug application
Compass Pathways PLC expected to post a loss of 45 cents a share - Earnings Preview